Not approv_老虎社区_美港股上老虎

am56
2021-10-27

Not approved yet[白眼]

Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in UK<blockquote>Novavax在英国申请其COVID-19疫苗授权，盘前交易中股价上涨超过6%</blockquote>

Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in

Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in UK<blockquote>Novavax在英国申请其COVID-19疫苗授权，盘前交易中股价上涨超过6%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":855325470,"tweetId":"855325470","gmtCreate":1635338929054,"gmtModify":1635338929154,"author":{"id":3584247049802991,"idStr":"3584247049802991","authorId":3584247049802991,"authorIdStr":"3584247049802991","name":"am56","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Not approved yet<span>[白眼]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p>Not approved yet<span>[白眼]&nbsp;</span></p></body></html>","text":"Not approved yet[白眼]","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/855325470","repostId":1102566887,"repostType":4,"repost":{"id":"1102566887","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635338367,"share":"https://www.laohu8.com/m/news/1102566887?lang=zh_CN&edition=full","pubTime":"2021-10-27 20:39","market":"us","language":"en","title":"Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in UK<blockquote>Novavax在英国申请其COVID-19疫苗授权，盘前交易中股价上涨超过6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102566887","media":"Tiger Newspress","summary":"Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in","content":"<p>Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in UK.<img src=\"https://static.tigerbbs.com/bd43c7012ce44c23ad7b68acc5cd612c\" tg-width=\"773\" tg-height=\"565\" width=\"100%\" height=\"auto\">The&nbsp;company&nbsp;today announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate. Its application for Conditional Marketing Authorization (CMA) marks the first submission for authorization of a protein-based COVID-19 vaccine in the United Kingdom.</p><p><blockquote>Novavax在英国申请其COVID-19疫苗授权后，盘前交易中股价上涨超过6%。该公司今天宣布完成向英国药品和保健品监管局(MHRA)提交的滚动监管申请，以获得其COVID-19候选疫苗的授权。其有条件上市许可（CMA）申请标志着英国首次提交基于蛋白质的COVID-19疫苗的授权。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in UK<blockquote>Novavax在英国申请其COVID-19疫苗授权，盘前交易中股价上涨超过6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in UK<blockquote>Novavax在英国申请其COVID-19疫苗授权，盘前交易中股价上涨超过6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-27 20:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in UK.<img src=\"https://static.tigerbbs.com/bd43c7012ce44c23ad7b68acc5cd612c\" tg-width=\"773\" tg-height=\"565\" width=\"100%\" height=\"auto\">The&nbsp;company&nbsp;today announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate. Its application for Conditional Marketing Authorization (CMA) marks the first submission for authorization of a protein-based COVID-19 vaccine in the United Kingdom.</p><p><blockquote>Novavax在英国申请其COVID-19疫苗授权后，盘前交易中股价上涨超过6%。该公司今天宣布完成向英国药品和保健品监管局(MHRA)提交的滚动监管申请，以获得其COVID-19候选疫苗的授权。其有条件上市许可（CMA）申请标志着英国首次提交基于蛋白质的COVID-19疫苗的授权。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102566887","content_text":"Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in UK.The company today announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate. Its application for Conditional Marketing Authorization (CMA) marks the first submission for authorization of a protein-based COVID-19 vaccine in the United Kingdom.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1813,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Novavax jumped over 6% in premarket trading as it filed for authorization of its COVID-19 vaccine in UK<blockquote>Novavax在英国申请其COVID-19疫苗授权，盘前交易中股价上涨超过6%</blockquote>

评论（3）

热议股票